Data from Late Stage Pipelines Presented at ACNP


Listen to learn more about the 2 late-stage psychiatric compounds discussed at the virtual ACNP meeting.

Armin Szegedi, MD, PhD, talks about the data Sunovion presented on two of its late-stage investigational psychiatric compounds at the American College of Neuropsychopharmacology (ACNP) virtual meeting.

See more highlights from the ACNP meeting here.

Dr Szegedi is Chief Medical Officer of Sunovion Pharmaceuticals Inc, a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions.

Dr Szegedi joined Sunovion in 2020 and serves as a member of the company’s Executive Leadership Team. He is responsible for leading clinical development strategy and implementation. As Chief Medical Officer he also oversees all aspects of clinical research and operations, data science, regulatory affairs, product and project management and pharmacovigilance.

An accomplished leader in pharmaceutical drug development since 2005, Dr Szegedi has applied his scientific and clinical expertise across a range of psychiatric and neurological therapeutic areas. Prior to joining Sunovion he held clinical leadership roles at Allergan, Forest, Merck, Schering-Plough and Organon, and led clinical development teams that achieved FDA approvals of Vraylar®, Ubrelvy™, and Saphris®.

A psychiatrist by training, Dr Szegedi received his MD and PhD from Johannes Gutenberg‐University in Mainz, Germany. His medical experience includes more than 12 years in clinical practice treating patients with psychiatric and neurological conditions. Dr Szegedi was a professor of clinical psychiatry at the Charité University Medicine Berlin and a clinical researcher in academia for over a decade, conducting studies in schizophrenia, depression, and other indications.

He is the author or co‐author of more than 100 peer‐reviewed publications and a member of the American College of Neuropsychopharmacology (ACNP).

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
© 2024 MJH Life Sciences

All rights reserved.